{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T16:35:42Z","timestamp":1790181342736,"version":"4.1.0"},"reference-count":16,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,1,27]],"date-time":"2022-01-27T00:00:00Z","timestamp":1643241600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,1,27]],"date-time":"2022-01-27T00:00:00Z","timestamp":1643241600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Neurol"],"published-print":{"date-parts":[[2022,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Myasthenia gravis (MG) is an auto-immune disease, and the mainstay of therapy is immunomodulation. Such patients are at high risk of acquiring any infections. Hence, we sought to determine the impact of the current global pandemic COVID-19 infection in MG patients.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      For our study, we used Cerner Real-World Data\n                      <jats:sup>TM<\/jats:sup>\n                      that was provided through Cerner\u2019s HealtheDataLab research tool. We ran a database query from January 2019 to July 2020 in our study and identified myasthenia patients with and without COVID-19 infection. To extract these patients\u2019 data, we used ICD 9-CM, ICD-10, and SNOMED-CT codes. We reported the data using means, range, and prevalence rates, and the p-values were calculated using the two-sample t-test and Pearson\u2019s chi-squared test.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      In the COVID-19 data set, a total of twenty-seven myasthenia patients were identified with a positive COVID-19 infection, and four were diagnosed with an exacerbation. The male to female ratio was equal and one unknown gender (3.7%) with a mean (\u00b1 SD) age of 64.33\u2009\u00b1\u200918.42\u2009years. This study group was compared with a non-COVID-19 data set in which a total of sixty-four myasthenia patients were identified, and twenty-three had an exacerbation. Among the 13 hospitalized patients in the two groups, the mean length of hospitalization for the myasthenia patients in the COVID-19 data set was 8.28\u2009days (\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u20097), and the non-COVID-19 set was 4.33\u2009days (n\u2009=\u20096), and it was statistically significant (p-value= 0.007).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>The mean length of hospital stay is prolonged in myasthenia patients who tested positive for COVID-19.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12883-022-02564-x","type":"journal-article","created":{"date-parts":[[2022,1,27]],"date-time":"2022-01-27T06:02:49Z","timestamp":1643263369000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":15,"title":["Impact of COVID-19 infection among myasthenia gravis patients- a Cerner Real-World DataTM study"],"prefix":"10.1186","volume":"22","author":[{"given":"Lakshmi Prasanna","family":"Digala","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shivika","family":"Prasanna","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Praveen","family":"Rao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adnan I.","family":"Qureshi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raghav","family":"Govindarajan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,1,27]]},"reference":[{"issue":"3","key":"2564_CR1","doi-asserted-by":"publisher","first-page":"408","DOI":"10.1111\/cei.12217","volume":"175","author":"JP Sieb","year":"2014","unstructured":"Sieb JP. Myasthenia gravis: an update for the clinician. Clin Exp Immunol. 2014;175(3):408\u201318.","journal-title":"Clin. Exp. Immunol."},{"key":"2564_CR2","first-page":"299","volume-title":"Neurological and Neurosurgical Intensive Care","author":"AH Ropper","year":"2004","unstructured":"Ropper AH, Gress DR, Diringer MN, et al. Treatment of the Critically Ill Patient With Myasthenia Gravis. In: Neurological and Neurosurgical Intensive Care. 4th ed. Philadelphia: Lipincott Williams & Wilkins; 2004. p. 299\u2013311.","edition":"4"},{"issue":"1","key":"2564_CR3","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1177\/1941875210382918","volume":"1","author":"LC Wendell","year":"2011","unstructured":"Wendell LC, Levine JM. Myasthenic crisis. Neurohospitalist. 2011;1(1):16\u201322.","journal-title":"Neurohospitalist."},{"key":"2564_CR4","doi-asserted-by":"crossref","unstructured":"Lotfi M, Hamblin MR, Rezaei N. COVID-19: Transmission, prevention, and potential therapeutic opportunities. Clinica Chimica Acta. 2020 May 29.","DOI":"10.1016\/j.cca.2020.05.044"},{"key":"2564_CR5","unstructured":"Cerner corporation. URL: https:\/\/www.cerner.com\/newsroom\/cerner-provides-access-to-de-identified-patient-data-for-covid-19-research-and-vaccine-development. Published April 24, 2020. Accessed November 2020."},{"issue":"12","key":"2564_CR6","doi-asserted-by":"publisher","first-page":"970","DOI":"10.1016\/S1474-4422(20)30413-0","volume":"19","author":"S Muppidi","year":"2020","unstructured":"Muppidi S, Guptill JT, Jacob S, et al. COVID-19-associated risks and effects in myasthenia gravis (CARE-MG). Lancet Neurol. 2020;19(12):970\u20131.","journal-title":"Lancet Neurol"},{"key":"2564_CR7","doi-asserted-by":"crossref","unstructured":"Delly F, Syed MJ, Lisak RP, Zutshi D. Myasthenic crisis in COVID-19. J. Neurol. Sci. 2020; 414:116888.","DOI":"10.1016\/j.jns.2020.116888"},{"issue":"Preprint","key":"2564_CR8","first-page":"1","volume":"30","author":"SB Ramaswamy","year":"2020","unstructured":"Ramaswamy SB, Govindarajan R. COVID-19 in Refractory Myasthenia Gravis-A Case Report of Successful Outcome. J. Neuromuscul. Dis. 2020 May 30(Preprint):1\u20134.","journal-title":"J. Neuromuscul. Dis."},{"key":"2564_CR9","doi-asserted-by":"crossref","unstructured":"Anand P, Slama MC, Kaku M, et al. COVID-19 in patients with myasthenia gravis. Muscle Nerve. 2020;62(2):254\u20138.","DOI":"10.1002\/mus.26918"},{"key":"2564_CR10","doi-asserted-by":"publisher","first-page":"1053","DOI":"10.3389\/fneur.2020.01053","volume":"11","author":"AE Camelo-Filho","year":"2020","unstructured":"Camelo-Filho AE, Silva A, Estephan EP, et al. Myasthenia gravis and COVID-19: clinical characteristics and outcomes. Front Neurol. 2020;11:1053.","journal-title":"Front Neurol"},{"key":"2564_CR11","doi-asserted-by":"crossref","unstructured":"Yang J, Zheng Y, Gou X, et al., Prevalence of comorbidities and its effects in patients infected with SARS-CoV-2: a systematic review and meta-analysis. Int J Infect Dis. 2020; 94: 91\u201395.","DOI":"10.1016\/j.ijid.2020.03.017"},{"issue":"5","key":"2564_CR12","doi-asserted-by":"publisher","first-page":"2000547","DOI":"10.1183\/13993003.00547-2020","volume":"55","author":"WJ Guan","year":"2020","unstructured":"Guan WJ, Liang WH, Zhao Y, et al. Comorbidity and its impact on 1590 patients with Covid-19 in China: A Nationwide Analysis. Eur Respir J. 2020;55(5):2000547.","journal-title":"Eur Respir J"},{"key":"2564_CR13","doi-asserted-by":"crossref","unstructured":"Jacob S, Muppidi S, Guidon A, et al. Guidance for the management of myasthenia gravis (MG) and Lambert-Eaton myasthenic syndrome (LEMS) during the COVID-19 pandemic. J. Neurol. Sci.\u00a02020;412:116803.","DOI":"10.1016\/j.jns.2020.116803"},{"key":"2564_CR14","doi-asserted-by":"publisher","first-page":"693","DOI":"10.1002\/mus.26689","volume":"60","author":"RR Gummi","year":"2019","unstructured":"Gummi RR, Kukulka NA, Deroche CB, et al., Factors associated with acute exacerbations of myasthenia gravis. Muscle and Nerve. 2019; 60:693\u2013699.","journal-title":"Muscle and Nerve"},{"key":"2564_CR15","doi-asserted-by":"crossref","unstructured":"Jani-Acsadi A, Lisak RP. Myasthenic crisis: guidelines for prevention and treatment. J. Neurol. Sci. 2007;261(1-2):127\u201333.","DOI":"10.1016\/j.jns.2007.04.045"},{"key":"2564_CR16","doi-asserted-by":"crossref","unstructured":"Sipil\u00e4 JO, Soilu-H\u00e4nninen M, Rautava P, et al., Hospital admission and prevalence trends of adult myasthenia gravis in Finland in 2004\u20132014: A retrospective national registry study. J. Neurol. Sci. 2019; 407:116520.","DOI":"10.1016\/j.jns.2019.116520"}],"container-title":["BMC Neurology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12883-022-02564-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12883-022-02564-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12883-022-02564-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,1,27]],"date-time":"2022-01-27T06:03:10Z","timestamp":1643263390000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcneurol.biomedcentral.com\/articles\/10.1186\/s12883-022-02564-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,1,27]]},"references-count":16,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2022,12]]}},"alternative-id":["2564"],"URL":"https:\/\/doi.org\/10.1186\/s12883-022-02564-x","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-289348\/v1","asserted-by":"object"}]},"ISSN":["1471-2377"],"issn-type":[{"value":"1471-2377","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,1,27]]},"assertion":[{"value":"1 March 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 January 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 January 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study protocols were approved by the Institutional review of Board committee at University of Missouri Columbia. All methods were carried out in accordance with relevant guidelines and regulations of the committee. The ethic committee waived the informed consent as it is de-identified data.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Lakshmi P Digala has no competing interest to disclose. Shivika Prasanna has no competing interest to disclose. Praveen Rao has no competing interest to disclose. Adnan I Qureshi has no competing interest to disclose.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"38"}}